文献速递胸部肿瘤放疗

局限期小细胞肺癌的合并症:年龄调整Charlson合并症指数及其与放化疗后总生存期的关联

Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-07-24

该回顾性研究分析了2003至2017年间367例接受胸部放化疗的局限期小细胞肺癌患者,评估年龄调整Charlson合并症指数(ACCI)对总生存期的预测价值。ACCI>6组中位总生存期11个月,显著短于ACCI≤6组的20个月(p=0.005);多因素分析显示ACCI>6与总生存期显著相关(HR 1.5,95%CI 1.0-2.1,p=0.049)。作者认为ACCI可能有助于识别生存期较短的患者,并用于风险分层和肿瘤学决策。

要点

  • ACCI>6组中位总生存期11个月,ACCI≤6组20个月,差异显著(p=0.005)。
  • 多因素分析中,预防性颅脑照射与总生存期显著相关(HR 0.6,95%CI 0.4-0.9,p=0.022)。
  • 多因素分析中,ACCI>6与总生存期显著相关(HR 1.5,95%CI 1.0-2.1,p=0.049)。

核心结论

  • 合并症与接受胸部放化疗的局限期小细胞肺癌患者生存期显著相关。
  • ACCI可能是识别生存期较短患者的有价值工具,并可能用于风险分层和肿瘤学决策。

研究设计与样本

  • 回顾性分析2003年至2017年间367例接受胸部放化疗的局限期小细胞肺癌患者,评估ACCI(n=348)对总生存期的预测价值。

主要发现

  • ACCI>6组中位总生存期11个月,ACCI≤6组20个月,差异显著(p=0.005)。
  • 单因素分析中,ACCI>6(HR 1.7,95%CI 1.2-2.4,p=0.003)、预防性颅脑照射(HR 0.5,95%CI 0.3-0.7,p<0.001)和Karnofsky体能状态≤70%(HR 1.4,95%CI 1.1-1.90,p=0.015)与总生存期显著相关。
  • 多因素分析中,预防性颅脑照射(HR 0.6,95%CI 0.4-0.9,p=0.022)和ACCI>6(HR 1.5,95%CI 1.0-2.1,p=0.049)与总生存期显著相关。

关键数值与推荐

  • 322例(88%)患者接受铂类胸部放化疗(顺铂或卡铂),37例(10%)接受长春新碱类胸部放化疗。
  • 中位放疗剂量60 Gy(范围24-66 Gy)。
  • 303例(83%)患者接受预防性颅脑照射(30 Gy,分2 Gy/次)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined, platinum-based thoracic chemoradiotherapy (TCR) is the current state-of-the-art treatment for patients with limited disease (LD) small-cell lung cancer (SCLC). There is only limited data available regarding the effect of comorbidities on survival following TRC. The purpose of this study is to assess the age-adjusted Charlson comorbidity index (ACCI) as a predictor of overall survival in LD-SCLC patients undergoing TCR. PATIENTS AND METHODS: We retrospectively analyzed 367 SCLC patients diagnosed with LD-SCLC who received TCR between 2003 and 2017. We evaluated the ACCI (n = 348) as a predictor of overall survival (OS). In this cohort, 322 patients (88%) received platinum-based TCR (either cisplatin or carboplatin), and 37 (10%) patients received vincristine based TCR. Median radiation dose was 60 Gy (range 24-66 Gy). Additionally, 83% of patients (n = 303) received prophylactic cranial irradiation (PCI, 30 Gy in 2 Gy fractions). Kaplan-Meier survival analysis was performed for OS. For comparison of survival curves, Log-rank (Mantel-Cox) test was used. Univariate and multivariate Cox proportional-hazards ratios (HRs) were used to assess the influence of cofactors on OS. RESULTS: Patients with an ACCI > 6 had a significantly shorter OS compared with patients with an ACCI ≤ 6 (median 11 vs. 20 months; p = 0.005). Univariate analysis for OS revealed a statistically significant effect for ACCI > 6 (HR 1.7; 95% CI 1.2-2.4; p = 0.003), PCI (HR 0.5; 95% CI 0.3-0.7; p < 0.001), and Karnofsky performance status ≤ 70% (KPS) (HR 1.4; 95% CI 1.1-1.90; p = 0.015). In multivariate analysis, OS was significantly associated with PCI (HR 0.6; 95% CI 0.4-0.9; p = 0.022) and ACCI > 6 (HR 1.5; 95% CI 1.0-2.1; p = 0.049). CONCLUSION: Comorbidity is significantly associated with survival in patients with LD-SCLC undergoing TCR. The ACCI may be a valuable tool to identify patients with a shorter survival and thus might be used for risk stratification and oncological decision making.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fink CA, Weykamp F, Adeberg S, et al. Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy. Clin Transl Radiat Oncol. 2023. PMID: 37564923. doi:10.1016/j.ctro.2023.100665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。